DFS and OS rates by randomization and subgroups
| . | 4-year DFS, % . | 4-year OS, % . |
|---|---|---|
| Intention to treat (Figure 2) | ||
| Investigational | 33.6 | 41.3 |
| Standard | 35.9 | 41.9 |
| Received autologous HCT (Figure 3) | ||
| Investigational | 40.8 | 50.8 |
| Standard | 41.3 | 43.9 |
| Daunorubicin dose/cytogenetic-risk/received autologous HCT (Figure 5) | ||
| 45mg/m2, favorable | 50 | 65.5 |
| 45mg/m2, intermediate | 39.1 | 35.6 |
| 90mg/m2, favorable | 60 | 80 |
| 90 mg/m2, intermediate | 40 | 49.3 |
| FLT3-ITD (not shown) | ||
| Positive | 23.4 | 25.7 |
| Negative | 37.0 | 45.8 |
| MLL-PTD (not shown) | ||
| Positive | 15.4 | 19.2 |
| Negative | 34.5 | 41.8 |
| Total CD34+ cells infused (Figure 6) | ||
| ≤ 5 × 106/kg | 29.5 | 36.4 |
| 5 × 106 to 7 × 106/kg | 49.6 | 55.9 |
| > 7 × 106/kg | 68.4 | 67.0 |
| . | 4-year DFS, % . | 4-year OS, % . |
|---|---|---|
| Intention to treat (Figure 2) | ||
| Investigational | 33.6 | 41.3 |
| Standard | 35.9 | 41.9 |
| Received autologous HCT (Figure 3) | ||
| Investigational | 40.8 | 50.8 |
| Standard | 41.3 | 43.9 |
| Daunorubicin dose/cytogenetic-risk/received autologous HCT (Figure 5) | ||
| 45mg/m2, favorable | 50 | 65.5 |
| 45mg/m2, intermediate | 39.1 | 35.6 |
| 90mg/m2, favorable | 60 | 80 |
| 90 mg/m2, intermediate | 40 | 49.3 |
| FLT3-ITD (not shown) | ||
| Positive | 23.4 | 25.7 |
| Negative | 37.0 | 45.8 |
| MLL-PTD (not shown) | ||
| Positive | 15.4 | 19.2 |
| Negative | 34.5 | 41.8 |
| Total CD34+ cells infused (Figure 6) | ||
| ≤ 5 × 106/kg | 29.5 | 36.4 |
| 5 × 106 to 7 × 106/kg | 49.6 | 55.9 |
| > 7 × 106/kg | 68.4 | 67.0 |